A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Subjects With Parkinson's Disease
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Nov 2019
Price : $35 *
At a glance
- Drugs DNL-201 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Denali Therapeutics Inc
- 20 Nov 2019 Planned End Date changed from 1 Sep 2019 to 1 Dec 2020.
- 20 Nov 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Dec 2020.
- 20 Nov 2019 Status changed from recruiting to active, no longer recruiting.